Research and Clinical Trials
Clinical trials help researchers develop new medicines and medical therapies. Here are some of the research projects currently at Mount Sinai.
Pilot Study to Assess the Efficacy & Safety of H.P. Acthar® Gel in Subjects With Relapsing-remitting Multiple Sclerosis
This is a multicenter, multiple dose study to estimate the response rate and examine the safety of H.P. Acthar® Gel (Acthar) in subjects with RRMS who have not responded to high dose steroids. We will use approximately 66 subjects. This trial is open to patients above the age of 18.
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)
The purpose of this study is to demonstrate the superiority of MD1003 over placebo in the disability of patients suffering from progressive multiple sclerosis, especially those with gait impairment. Researchers are interested in subjects between ages 18 and 65, both men and women.
Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects with Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)
This clinical study compares the efficacy, safety, and tolerability of therapy with ponesimod vs placebo in subjects with active RMS who are treated with DMF (Tecfidera®). This study is open to patients between ages 18 and 55.
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
This study evaluates the efficacy and safety of ocrelizumab in participants with RRMS who have had a suboptimal response to an adequate course of DMT. Participants receive ocrelizumab as an initial dose of two 300-milligrams (mg) intravenous (IV) infusions (600 mg total) separated by 14 days. Then they receive one 600-mg IV infusion for a maximum of four doses (up to 96 weeks). Participants spend about 96 weeks in the study. Researchers are looking for patients between ages 18 and 55.
Endpoint Calibration for a Phase 2 Study of Lisinopril in Multiple Sclerosis
This study aims to calibrate the Multiple Sclerosis Functional Composite (MSFC) for home implementation in a phase 2 trial of lisinopril in multiple sclerosis. In this initial stage, participants come to the study site one day a week for three weeks to complete the MSFC. They also complete the MSFC at home once weekly for three weeks using remote sensing technology and video conferencing. The study is open to patients between ages 18 and 64.
Efficacy & Safety of RPh201 Treatment in Patients with Previous Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
This study is designed as a double-masked, randomized, placebo-controlled, pivotal clinical study to evaluate the efficacy and safety of subcutaneous (SC) administration of RPh201 in participants with previous NAION. Researchers are looking for patients over age 50.